Objectives: To assess the cost-effectiveness of mirabegron 50 mg relative to tolterodine extended release 4 mg for the treatment of overactive bladder if used as the first-line treatment in Japan. Methods: A Markov model was developed to simulate the cost-effectiveness of the mirabegron first-line treatment (and tolterodine second-line) versus tolterodine first-line treatment (and mirabegron second-line) taken for 5 years from the randomized European-Australian study (SCORPIO trial) and single technology appraisal assessment report by the National Institute for Health and Care Excellence. The incremental costeffectiveness ratio was calculated with utility value by quality-adjusted life year with cost using the medical fee and the drug price tariff in 2016. For the study of transition of treatment status, our analytical model was established. The transition probabilities of severity states were calculated based on the probabilities for the mean numbers of incontinence episodes/day and micturition episodes/day in mirabegron-treated and tolterodine-treated patients in the single technology appraisal assessment report. Results: The 5-year expected effect per patient was 3.860 quality-adjusted life years for first-line mirabegron and 3.839 quality-adjusted life years for first-line tolterodine. The 5-year expected cost per patient was ¥526 191 for first-line mirabegron, and ¥472 390 for first-line tolterodine. The incremental cost-effectiveness ratio was ¥2 565 927/qualityadjusted life year. This value was below the willingness-to-pay threshold of ¥5 million/ quality-adjusted life year. In more severe states, the incremental cost-effectiveness ratio exceeded ¥5 million. Conclusions: First-line mirabegron appears to be more cost-effective than first-line tolterodine. In patients with severe symptoms, first-line mirabegron is not economically preferable.
Introduction
It is necessary to appropriately use limited medical resources when using a new medical technology or novel medication, resulting in wider use of pharmacoeconomic assessment. Recent pharmacoeconomic studies have frequently evaluated to what degree a target drug is economically superior to a comparator drug. For example, first-line use of a new drug is evaluated as to whether the new drug is cost-effective compared with first-line treatment of an existing drug. It is usual practice in the actual treatment of OAB to replace a first-line drug with another medication when it is impossible to continue the former drug as a result of adverse reactions. The NICE recommends Mira for OAB patients for whom anti-M drugs are not suitable. The Japanese guideline of OAB treatment recommends Mira even in initial treatment. 1 In the clinical setting, however, it is still frequent practice to use anti-M drugs in first-line treatment, and Mira in second-line treatment. In the present study, we developed an original analytical model to assess whether it is economically acceptable to recommend firstline Mira therapy. With this model, we analyzed the cost-effectiveness of Mira from the viewpoint of public healthcare payers. This model incorporates the order of drug selection, showing close resemblance to the clinical setting. This model therefore shows which drug is more efficient as first-line treatment, supplying useful information for treatment selection in the clinical setting, and establishment of treatment guidelines in Japan.
Methods
The present study was based on published articles and disclosed data, requiring no ethical review.
Development of analytical models
To develop our analytical model, we referred to data from previous pharmacoeconomic studies of anti-M drugs, 2-7 the phase III study of Mira SCORPIO 8 and STA report by the NICE. 9 For the time-course of untreated patients for whom it was impossible to refer to existing data, it was difficult to estimate the time-course from existing literature. The authors made an assumption, from our clinical data.
Our analytical model was established based on the transitions of the following two parameters: "transition of treatment status" and "transition of OAB symptoms based on treatment efficacy (mean numbers of micturition episodes and incontinence episodes)."
Transition of treatment status
In our original analytical model in the present study, first-line treatment used Mira or the anti-M drug Tol and, considering treatment discontinuation and restart, second-line treatment used the other drug that was not used in first-line treatment. The analytical period was set at 5 years. The two drugs were given based on the standard dosage and administration, one 50-mg tablet once daily for Mira, and one 4-mg capsule once daily for Tol.
We developed an original Markov model, because Markov models are frequently used in the model analyses of chronic diseases including OAB. We used a Markov model to simulate whether an OAB patient continues first-line treatment, discontinues the treatment and switches to second-line treatment, receives no treatment or restarts OAB treatment every month.
For treatment status, the following parameters were used: "treatment continuation," "percentage of treatment discontinuation," "probability of switch from first-line treatment to second-line treatment" and "probability of treatment restart" (Fig. 1) . Based on reports describing that the probability of OAB treatment discontinuation, adverse events and limited efficacies are primary reasons for discontinuation of anticholinergic drugs. [10] [11] [12] The efficacies of Tol and Mira were assumed to be equivalent. 8 As no real-life data were available for persistence with Mira, the model assumed that discontinuation rates without adverse events were similar for Mira and Tol. 9, 10, 13 Adverse events for anticholinergic drugs include dry mouth and constipation. The incidences of the two events significantly differed between Mira and Tol in the SCORPIO study. 8 After treatment discontinuation, the probability was set at 26.1% for a switch to second-line treatment, and 73.9% for a switch to no treatment.
14 The probability of treatment restart after a switch to no treatment was set at 5.6%; the percentage of restart was set at 33.3% for first-line treatment and 66.7% for second-line treatment (Table 1 ).
9,13
Transition of OAB symptoms based on treatment efficacy
The cycle length was set at 1 month, and there were 60 transition cycles in 5 years. It was assumed that parameters representing OAB symptoms; that is, the mean numbers of micturition episodes per day and incontinence episodes per day, would change based on treatment efficacy. The mean numbers of micturition episodes per day and incontinence episodes per day were combined to define the severity state of OAB. The severity states were classified into 25 states from A to Y (Table 2) . In each cycle, the severity state changed from any of the 25 states from A to Y to any of the 25 states including the state concerned in this cycle (Fig. 2) .
The transition probabilities of severity states were calculated based on the probabilities for the mean numbers of incontinence episodes per day and micturition episodes per day in Mira-treated and Tol-treated patients in the STA report.
It was assumed that treatment effect reached the plateau at month 3, and that the severity state remained the same at month 4 and subsequent time-points, even in patients who continued treatment. This assumption was based on the findings that the anti-M drug, fesoterodine, remained effective for 2 years after month 4 in a long-term safety study of OAB patients, 15 and Mira was suggested to be similarly effective in a long-term safety study. 16, 17 For the transition probability of no treatment, no data were available from any previous study or report. The following from our clinical data were adopted: from our clinical data, approximately half of the patients who stopped treatment aggravated and restarted the treatment (data not shown). Thus, we assumed the aggravation in 11.2% (double of the restart rate of 5.6%) receiving no treatment per cycle. Symptoms were considered to worsen when the mean number of micturition episodes per day or incontinence episodes per day was increased by one step.
Overview of analytical model
We developed a Markov model that incorporated "transition of treatment status ( Fig. 1 )" and "transition between severity states based on treatment effectiveness ( Fig. 2 )" (Fig. 3) . We evaluated pharmacoeconomics of Mira with this analytical model.
Input data

Effectiveness index
This analysis used the QALY to evaluate the treatment effect. The QALY, a health outcome measure that considers the survival year and QOL, was a weighted QOL by regarding "completely in good health = 1" and "death = 0." By the 25 severity states of OAB, the utility value of EQ-5D scores from the SCORPIO study was used ( Table 2) .
The severity state changed (including to be the same) every month in our analytical model, and the EQ-5D score also changed. Monthly EQ-5D scores were totaled to calculate the utility value for 60 cycles during the 5-year period. The expected effectiveness (QALY) of a total of 5 years was calculated individually for Mira 1st and Tol 1st.
Cost items
Cost items were public medical fees in Japan; that is, medical fee, dispensing fee and medication fee ( Table 3) . The above fees were calculated based on the medical cost reimbursement point table in fiscal year 2016.
The 5-year analytical period include the periods of both treatment and no treatment, along with the transition of treatment status in each analytical model. The cost was calculated monthly. Mira or Tol was prescribed during the administration period, leading to initiation of the prescription, dispensing and medication fees, along with the monthly follow-up visit fee. During the no treatment period, in contrast, the follow-up visit fee was the only cost.
It was assumed that ultrasound, and qualitative and semiquantitative tests of urinary general substances were carried out every 3 months with or without treatment.
These costs per month were accumulated for 5 years; that is, 60 months, individually for Mira 1st and Tol 1st to calculate expected costs. Table 2 shows the distribution of the mean numbers of micturition episodes per day and incontinence episodes per day Treatment discontinuation and switch parameters (per month). based on the STA report. Our analysis was started on the distribution of OAB patients that was assumed from this table.
Distribution of OAB patients at treatment initiation
Methods of cost-effectiveness analysis
Basic analysis
The cost-effectiveness of Mira was evaluated with the ICER. The ICER shows the incremental cost that is required for Mira 1st to obtain one more QALY compared with Tol 1st.
In the present analysis, the acceptable upper limit (willingness-to-pay threshold) of the ICER was set at ¥5 million/ QALY. 18 Mira was evaluated to be economically acceptable when its ICER was below this threshold.
Discount rate
In the present study, the annual discounting rate was 2% in the basic analysis. 19 
Sensitivity analysis
Within AE5% of basic analytical values for data from the SCORPIO trial; that is, the utility measured by EQ-5D, distribution of OAB patients and transition probabilities of treatment status and severity states, and a probabilistic sensitivity analysis was carried out by Monte Carlo simulation (calculation based on computer-generated random numbers by 5000 times).
Secondary analyses
The following three secondary analyses were carried out. First, the ICER was calculated by severity states at the diagnosis of OAB. This parameter was used to analyze differences in economic preferences by severity states at treatment initiation after the diagnosis of OAB.
The next analysis examined changes in the distribution of severity states during the 5-year period at OAB diagnosis in the Mira 1st or Tol 1st model. This analysis assessed which drug should be used as first-line for superior treatment effect.
Results
Basic analyses
The 5-year expected effect per patient was 3.860 QALYs for Mira 1st and 3.839 QALYs for Tol 1st. The 5-year expected cost per patient was ¥526 191 for Mira 1st and ¥472 390 for Tol 1st. ICER was ¥2 565 927/QALY. This ICER remained below the generally accepted willingness-to-pay threshold of ¥5 million/QALY. Figure 4 shows the results of the probabilistic sensitivity analysis of Mira 1st versus Tol 1st repeated. Figure 5 shows a cost-effectiveness acceptability curve with the ICER (¥/QALY).
Sensitivity analysis
These results of the probabilistic sensitivity analysis showed that the probability of ICER below the threshold of ¥5 million was 99.82%. There is no absolute standard for the probability of ICER within the threshold range, while ≥80% probabilities are acceptable. 20 It was therefore assessed that our analytical results were robust. 
Secondary analyses
ICER by severity states
In T and Y of more severe states based on the mean number of micturition episodes per day, the ICER exceeded ¥5 million ( Table 4 ). The ICER was below this threshold in other severity states. The ICER tended to be smaller in milder severity states.
Changes in severity states during treatment
During treatment, patient distributions to moderate-to-severe states of L, M, N, Q, R, S, V, W and X were reduced with increased distributions to relatively mild states of A, B and F (Fig. 6) .
In the Mira 1st model, the percentage of transition to relatively mild states of A and B was larger compared with the Tol 1st model. In contrast, the percentage of transition to the more severe category Y was larger in the Tol 1st model.
Discussion
The ICER for Mira 1st is ¥2 565 927/QALY, which was below the threshold of ¥5 million/QALY. 18 It was assessed from the results that Mira 1st was economically more preferable compared with Tol 1st. The robustness of these results was adequately verified by the probabilistic sensitivity analysis showing that the probability of ICER being <5 million/QALY was 99.82%. These results showed that the efficacy of Mira overcame the higher list price of this drug compared with Tol. The list price (per month) of Mira was higher by ¥300, and the 5-year expected cost of Mira 1st was also higher, ¥526 191, compared with ¥472 390 of Tol 1st. The expected cost, however, included the medication fees of not only the first-line drugs, but also secondline drugs. The efficacy measure, QALY, of Mira 1st was superior, 3.860 QALYs, compared with 3.839 QALYs of Tol 1st, while the difference was not large. Similar to the medication fees, the treatment effect included the effect of not only the first-line drugs, but also second-line drugs. In a 1-year continuous treatment model from a previous study by Yamanishi et al., Mira alone and Tol alone were compared, with ICER of ¥1 460 650/QALY. 21 Use of secondline treatment in the present study significantly contributed to the substantial difference in the ICER compared with the present results.
The secondary analysis of the severity-specific ICER at diagnosis showed smaller ICERs in patients with milder conditions. These results clarified that Mira 1st was economically acceptable and should positively be used in patients with mild symptoms of OAB. In patients who were classified into T or Y, however, the ICER exceeded ¥5 million/QALY, showing that Mira 1st was not economically preferable (Table 4) . It is possible that, for improvement of severe OAB symptoms, options other than Mira should be considered, and that Mira should be combined with such drugs as anti-M drugs. 22 Examining changes in severity states during 5 years in the Mira 1st model after treatment initiation (Fig. 6 ), there were decreased distributions to moderate-to-severe states of L, M, N, Q, R, S, V, W and X in both Mira 1st and Tol 1st models. The distribution rate to A substantially increased from 2.45% at baseline to 16.91% in the Mira 1st model and 16.42% in the Tol 1st model. The distribution rate to Y also increased from 3.02% to 4.24% and 6.06%, respectively. The probable reasons might be that OAB symptoms, especially severe symptoms, progress over time, which cannot be improved by pharmacotherapy. First-line treatment of either drug was effective, with a larger transition to Y in the Tol 1st model. The probable reasons could be that OAB might aggravate in patients in whom Tol 1st was inadequately effective because of shorter treatment durations as a result of its adverse reactions.
The aforementioned results showed that, in the Japanese public healthcare system, Mira 1st was economically acceptable in OAB treatment, and useful in efficient use of medical resources. In addition, many treatment guidelines recommend certain treatment options based on efficacy and safety data from randomized comparative studies, with very little use of pharmacoeconomic measures. As in the present study that carried out the pharmacoeconomic assessment of Mira, it is necessary to incorporate such evaluation measures to efficiently use limited medical resources and to improve the QOL of patients.
It is expected in Japan that OAB patients will increase further due to the aging society, requiring further pharmacoeconomic studies to carry out positive collection of treatment data in Japanese patients. It is also predicted that national medical expenses increase due to advancement of medical technology and rapid aging. For moderation in healthcare costs, the Diagnosis Procedure Combination was introduced for assessment of lump sum payments for admission fees. Use of generics and self-medication are also promoted. In addition, it is necessary in the clinical setting to use more economical medical technology and medications. Willingness to pay (¥/QALY) 2 500 000 3 000 000 3 500 000 4 500 000 5 000 000 4 000 000 1 000 000 It is hoped to promote further pharmacoeconomic studies, and to make use of data from such studies in establishment of treatment guidelines and selection of treatment in the clinical setting.
In pharmacoeconomic studies, model analyses and simulation set standard therapeutic outcomes rather than actual outcomes, specify strict inclusion and exclusion criteria, and use data from, for example, clinical studies that are carried out as specified in protocols. Results of pharmacoeconomic studies therefore do not necessarily reflect all variations in actual background characteristics of patients and physicians' therapeutic policies.
The comparison of ICER of Mira versus a placebo might also be important. In the present study, we selected Tol as the comparison of the active drug, because we wished to make a simulation model as a more clinically useful model.
The analysis between men and women is very important, but it is difficult to subanalyze, because there is no literature evaluating the comparison of Mira and anti-M separately between men and women.
It would be ideal to use the Japanese data for the pharmacoeconomic study in Japan. In the present study with pharmacoeconomics, we used EQ-5D for the pharmacoeconomic evaluation of drugs to evaluate QALY. However, EQ-5D was not evaluated in the clinical data in Japan. Therefore, we adopted STA reports in the UK.
As the cost-effectiveness of pharmacotherapy should depend individually on the national healthcare system, the present result is only valid in Japan and is not applied globally.
When new QOL data and data on such health outcomes as treatment effect in Japanese patients are available, it will be necessary to analyze these data again.
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